ArticleNeurochemical research2026
Intermittent Fasting Attenuates Cognitive Decline in D-Galactose-Induced Aging Rats in Association with β-Hydroxybutyrate and PI3K/AKT/GSK-3β Signaling.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Age-related cognitive decline is a major public health concern, with few effective interventions available. Intermittent fasting (IF) has emerged as a promising metabolic intervention, potentially enhancing neuroprotection through increased β-hydroxybutyrate (BHB) production. This study aimed to test the hypothesis that IF attenuates cognitive decline in D-galactose (D-gal)-induced aging rats, at least partly in association with BHB elevation and modulation of PI3K/AKT/GSK-3β signaling. Forty-six male Sprague-Dawley rats (2 months old) were assigned to five groups: Control, D-gal-induced aging (D-gal), D-gal + IF, D-gal + IF + LY294002 (a PI3K inhibitor), and D-gal + IF + Solvent. IF was administered for 6 weeks in conjunction with D-gal treatment. Recognition memory and spatial learning/memory were assessed using the novel object recognition and Morris water maze tests, respectively; the open field test was used to evaluate locomotor activity and anxiety-like behavior. Biochemical assays (ELISA, Western blot), histological staining, and RNA-seq transcriptomic analysis were performed. IF improved recognition memory and spatial learning/memory, preserved hippocampal neuronal morphology, increased the proportion of morphologically normal CA1 neurons, elevated serum BHB levels, reduced neuroinflammation and tau phosphorylation, and restored brain-derived neurotrophic factor (BDNF) expression. These improvements were attenuated by LY294002 intervention, supporting the involvement of the PI3K/AKT/GSK-3β pathway. Transcriptomic analysis revealed suppression of senescence-related genes and modulation of neuroprotective pathways. IF attenuated cognitive decline in D-gal-induced aging rats in association with increased BHB levels and modulation of the PI3K/AKT/GSK-3β pathway. These findings suggest that IF may represent a promising non-pharmacological intervention for age-related cognitive dysfunction, although causal roles of ketone metabolism require further validation.
Indexed as
Identifiers
42207407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.